Litcius/Paper detail

Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation

Rodrigo Martino, Irene García‐Cadenas, Albert Esquirol

2021Bone Marrow Transplantation26 citationsDOIOpen Access PDF

Topics & Concepts

DaratumumabMedicinePure red cell aplasiaABO blood group systemTransplantationImmunologyAplasiaOncologyMultiple myelomaBortezomibInternal medicineBone marrowBlood groups and transfusionHematopoietic Stem Cell TransplantationParvovirus B19 Infection Studies
Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation | Litcius